Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...
April 29 () - Pfizer said on Wednesday its drug Elrexfio met the main goal in a late-stage trial that tested the blood ...
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO® ...
Pfizer Inc. PFE on Wednesday shared topline results from the late-stage study of its cancer treatment, ELREXFIO (elranatamab) ...
Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...
Pfizer (NYSE:PFE) and Bristol Myers Squibb are making their blood thinner Eliquis available through the Mark Cuban Cost Plus ...
Final analysis: Pfizer's COVID-19 vaccine 95% effective, company to seek authorization within 'days'
A final analysis of a COVID-19 vaccine candidate produced by Pfizer and BioNTech shows that the drug is 95% effective in preventing the coronavirus, and the companies say they hope to apply for ...
Analysts highlight Pfizer and Medical Properties Trust (MPT) as attractive high-yield dividend stocks for April despite market volatility and economic uncertainty. Pfizer’s 6.4% forward yield is ...
(Reuters) -U.S. drugmaker Pfizer could work its connections within President Donald Trump's administration to try to thwart Novo Nordisk's surprise rival bid to acquire U.S. obesity biotech firm ...
This podcast comes from the DPHARM 2025 meeting. Pfizer details how they jointly co-designed and implemented an EDC/CDMS platform that’s fit for purpose. This session focuses on: Engaging all ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results